Home LiteratureArticle Details
PMID: 9341987 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia.

The Journal of laboratory and clinical medicine ·Vol. 130 ·No. 3 ·1997-09-00 ·Pages 278-84

Denomme GA, Warkentin TE, Horsewood P, Sheppard JA, Warner MN, Kelton JG

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder caused by heparin-dependent IgG (HIT-IgG) that recognizes a complex of heparin and platelet factor 4 (PF4), leading to platelet activation via the platelet Fc gammaIIa receptors (Fc gammaRIIa). Not all patients who generate HIT-IgG in response to heparin develop HIT, however, possibly because of observed differences in the ability of platelets from healthy individuals to be activated by HIT sera. It is known that a polymorphism in the platelet Fc gammaRIIa plays an important role in determining platelet reactivity to murine platelet-activating monoclonal antibodies of the IgG1 subclass: homozygous arg131 ("high responder" or HR) platelets respond well, and homozygous his131 ("low responder" or LR) platelets respond poorly, respectively, to these murine monoclonal antibodies. We sought to determine whether the differing risk for HIT among patients who receive heparin, as well as the variable platelet reactivity to HIT sera, could be explained by preferential activation by HIT-IgG of platelets bearing a particular Fc gammaRIIa phenotype. We found that the LR Fc gammaRIIa gene frequency was significantly overrepresented among 84 HIT patients, compared with that of 264 control subjects (0.565 versus 0.471; p = 0.03). We studied the subclass distribution of HIT-IgG against its major antigen, heparin/PF4 complexes, and found that 55 of 61 (90%) HIT sera expressed IgG1 antibodies either alone (n = 47) or in combination with IgG2 (n = 5) or IgG3 (n = 3). We then compared the platelet-activating profile of HIT sera with murine platelet-activating monoclonal antibodies. As expected, the murine IgG1 monoclonal antibodies preferentially activated platelets from homozygous HR individuals. In contrast, however, the LR homozygous platelets exhibited the greatest reactivity to HIT sera that contained predominantly anti-heparin/PF4 antibodies of the IgG1 subclass. We conclude that the significant overrepresentation of the LR (his131) gene among patients with HIT may be explained by the preferential activation of LR Fc gammaRIIa platelets by HIT antibodies of the IgG1 subclass, which is the predominant immunoglobulin subclass generated in HIT.

MeSH Terms
Antibodies, Monoclonal Anticoagulants/adverse effects,immunology Antigens, CD/genetics,immunology DNA Primers/chemistry DNA Probes/chemistry Gene Frequency Heparin/adverse effects,immunology Histidine/genetics Humans Immunoglobulin G/immunology Platelet Activation/immunology Platelet Factor 4/immunology Polymorphism, Genetic Receptors, IgG/genetics,immunology Thrombocytopenia/chemically induced,genetics
Chemicals
Antibodies, Monoclonal Anticoagulants Antigens, CD DNA Primers DNA Probes Fc gamma receptor IIA Immunoglobulin G Receptors, IgG Platelet Factor 4 Histidine Heparin
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Denomme G A
Department of Laboratory Medicine, Hamilton Health Sciences Corporation, Ontario, Canada.
Warkentin T E
Horsewood P
Sheppard J A
Warner M N
Kelton J G
Article Info
Journal
The Journal of laboratory and clinical medicine
Abbr.
J Lab Clin Med
ISSN
0022-2143
Published
1997-09-00
Pages
278-84
Language
English
Region
United States
NLM ID
0375375
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com